What sales remdesivir might make this year for Gilead is a burning question for investors, and clues emerged yesterday. 1-1.5 million treatment courses will be sold this year, executives predicted, and at $2,340 per course this equates to sales of $2-3.5bn. Gilead added $2bn to the upper end of its 2020 group sales guidance, which can probably be read as the company’s conservative take on where remdesivir, trademarked Veklury, could come in. This is substantially higher than sellside consensus, which sits just above $1bn; this figure had been gradually creeping higher over the past few weeks. Many analysts were waiting for this guidance to start modelling the product, so consensus is certain to now jump – SVB Leerink, among the most bullish of the banks, today more than doubled its 2020 number to $5.4bn. Not all are convinced that this will be achieved, largely because it would require major stockpiling. This is not happening yet because supply is being used immediately, though there might be enough surplus by October, Gilead said. It seems unlikely that executives would risk over-promising here, but opinions on where demand is heading in the coming months look set to remain split.